Owners, management and financials
CVR: 32323677
Previous names: ACP 30.06.2012 4 A/S, ASCENDIS PHARMA RELAXIN DIVISION A/S, ASCENDIS PHARMA, CIRCULATORY DISEASES DIVISION A/S
EUR -190,726,000
Gross profit
Net result: EUR -225,725,000
ASCENDIS PHARMA A/S (100%)
CVR · view owners
Jan Møller Mikkelsen
Board: Michael Wolff Jensen (chair) and 2 members
CVR · view management
Active
Founded 29 June 2012
CVR · view overview
0 employees
Annual report 2025 · average
Name registered: Ascendis Pharma Growth Disorders A/S
CVR · 04/11/2016
View the full event history
Ascendis Pharma Growth Disorders A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA, CIRCULATORY DISEASES DIVISION A/S and ASCENDIS PHARMA RELAXIN DIVISION A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR -190,726,000 and a net result of EUR -225,725,000 compared with EUR -176,019,000 the year before. Equity in the 2025 report amounted to EUR -723,740,000.
Selskabets formål er at udvikle ideer og præparater til sygdomsbekæmpelse ad medicinsk vej, at producere og sælge sådanne præparater eller ideer, at eje aktier i selskaber med samme formål samt at udøve virksomhed, som står i naturlig forbindelse hermed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -190.7 mio. EUR | -225.7 mio. EUR | 27.7 mio. EUR | -723.7 mio. EUR | 0 | |
| 202401/01/2024 – 31/12/2024 | -157.5 mio. EUR | -176 mio. EUR | 8.9 mio. EUR | -498 mio. EUR | 0 | |
| 202301/01/2023 – 31/12/2023 | -114.2 mio. EUR | -120.2 mio. EUR | 21.6 mio. EUR | -322 mio. EUR | 0 | |
| 202201/01/2022 – 31/12/2022 | -57 mio. EUR | -61.4 mio. EUR | 13.6 mio. EUR | -201.8 mio. EUR | 0 | |
| 202101/01/2021 – 31/12/2021 | -47.9 mio. EUR | -51 mio. EUR | 9.5 mio. EUR | -140.4 mio. EUR | 0 | |
| 202001/01/2020 – 31/12/2020 | -30.2 mio. EUR | -32.1 mio. EUR | 10.7 mio. EUR | -89.5 mio. EUR | 0 | |
| 201901/01/2019 – 31/12/2019 | -17.9 mio. EUR | -19 mio. EUR | 8.8 mio. EUR | -57.4 mio. EUR | 0 | |
| 201801/01/2018 – 31/12/2018 | -14.4 mio. EUR | -15.3 mio. EUR | 10.1 mio. EUR | -38.4 mio. EUR | 0 | |
| 201701/01/2017 – 31/12/2017 | -13.2 mio. EUR | -13.7 mio. EUR | 2.1 mio. EUR | -23 mio. EUR | 0 | |
| 201601/01/2016 – 31/12/2016 | -5.9 mio. EUR | -6.1 mio. EUR | 2 mio. EUR | -9.3 mio. EUR | - | |
| 201501/01/2015 – 31/12/2015 | -2.5 mio. EUR | -2.6 mio. EUR | 503 t. EUR | -3.2 mio. EUR | - | |
| 201401/01/2014 – 31/12/2014 | -507 t. EUR | -603 t. EUR | 454 t. EUR | -553 t. EUR | - | |
| 201301/01/2013 – 31/12/2013 | -23 t. | -33 t. | 1.2 mio. | 89 t. | - |
Compared to 129 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreThe CVR number of Ascendis Pharma Growth Disorders A/S is 32323677.
Ascendis Pharma Growth Disorders A/S is owned by ASCENDIS PHARMA A/S.
The management of Ascendis Pharma Growth Disorders A/S consists of Jan Møller Mikkelsen.
The board of Ascendis Pharma Growth Disorders A/S consists of Michael Wolff Jensen, Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen, with Michael Wolff Jensen as chair.
In 2025, Ascendis Pharma Growth Disorders A/S reported a gross profit of EUR -190,726,000.
Ascendis Pharma Growth Disorders A/S had an average of 0 employees in the 2025 financial year according to the annual report.
Claim this page to add your logo and social links. Free to get started.
Ascendis Pharma Growth Disorders A/S has published its annual report for 2025. Gross profit came to DKK -190,726,000, and the net result was DKK -225,725,000.
Ascendis Pharma Growth Disorders A/S has published its annual report for 2024. Gross profit came to DKK -157,522,000, and the net result was DKK -176,019,000.
Ascendis Pharma Growth Disorders A/S has published its annual report for 2023. Gross profit came to DKK -114,185,673, and the net result was DKK -120,223,434.
Ascendis Pharma Growth Disorders A/S has published its annual report for 2022. Gross profit came to DKK -57,035,666, and the net result was DKK -61,381,172.
Ascendis Pharma Growth Disorders A/S has published its annual report for 2021. Gross profit came to DKK -47,933,482, and the net result was DKK -50,957,882.
Ascendis Pharma Growth Disorders A/S has published its annual report for 2020. Gross profit came to DKK -30,184,950, and the net result was DKK -32,098,569.
Ascendis Pharma Growth Disorders A/S has published its annual report for 2019. Gross profit came to DKK -17,880,176, and the net result was DKK -19,025,880.
Ascendis Pharma Growth Disorders A/S has published its annual report for 2018. Gross profit came to DKK -14,434,891, and the net result was DKK -15,339,664.
Ascendis Pharma Growth Disorders A/S has published its annual report for 2017. Gross profit came to DKK -13,183,449, and the net result was DKK -13,676,348.
Ascendis Pharma Growth Disorders A/S has published its annual report for 2016. Gross profit came to DKK -5,944,352, and the net result was DKK -6,149,421.
On November 4, 2016, the company changed its name from ASCENDIS PHARMA, CIRCULATORY DISEASES DIVISION A/S to Ascendis Pharma Growth Disorders A/S.
Ascendis Pharma Growth Disorders A/S has published its annual report for 2015. Gross profit came to DKK -2,500,794, and the net result was DKK -2,641,290.
Ascendis Pharma Growth Disorders A/S has published its annual report for 2014. Gross profit came to DKK -507,089, and the net result was DKK -602,535.
On August 1, 2014, the company changed its name from ASCENDIS PHARMA RELAXIN DIVISION A/S to ASCENDIS PHARMA, CIRCULATORY DISEASES DIVISION A/S.
Ascendis Pharma Growth Disorders A/S has published its annual report for 2013. Gross profit came to DKK -22,831, and the net result was DKK -33,146.
On November 28, 2013, the company changed its name from ACP 30.06.2012 4 A/S to ASCENDIS PHARMA RELAXIN DIVISION A/S.
Ascendis Pharma Growth Disorders A/S has published its interim report for the period June 29, 2012 – December 31, 2012.
As of June 29, 2012, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Ascendis Pharma Growth Disorders A/S.
As of June 29, 2012, Michael Wolff Jensen has joined the board of directors of Ascendis Pharma Growth Disorders A/S.
As of June 29, 2012, Jan Møller Mikkelsen has joined the board of directors of Ascendis Pharma Growth Disorders A/S.
As of June 29, 2012, Anni Lotte Kirstine Pedersen has joined the board of directors of Ascendis Pharma Growth Disorders A/S.
As of June 29, 2012, Jan Møller Mikkelsen is registered as adm. dir. of Ascendis Pharma Growth Disorders A/S.
As of June 29, 2012, ASCENDIS PHARMA A/S is registered as an owner of Ascendis Pharma Growth Disorders A/S with an ownership share of 100%.
Ascendis Pharma Growth Disorders A/S was founded on June 29, 2012.
Companies in the same industry and area
CVR 29918791
CVR 32323502
CVR 32323537
CVR 37011185
CVR 46029518
